LOW:NYSELowe's Companies, Inc. Analysis
Data as of 2026-06-04 - not real-time
$207.65
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Lowe’s (LOW) is trading at $207.65, well above its DCF‑derived fair value of $100.82, signaling an **overvalued** pricing level. The stock sits under its 20‑day SMA ($218.98) and 50‑day SMA ($231.33), with a bearish MACD histogram and a 14‑day RSI of 32.9, suggesting short‑term momentum weakness despite being technically oversold. Fundamentally, the company posted a 10.3% revenue growth year‑over‑year, maintains a 33% gross margin and a 7.5% profit margin, and delivered earnings that beat estimates, though its full‑year outlook disappointed investors, prompting a 2.9% post‑earnings decline. The dividend remains attractive at 2.41% with a 40.6% payout ratio, supported by solid free cash flow of $4.8 B. Recent Citi upgrade adds a positive catalyst, but the bearish technical picture and a 27% downside relative to fair value temper enthusiasm.
Overall, while the business fundamentals and dividend profile are sound, the current market price reflects a premium that may be difficult to sustain without clearer guidance or a shift in market sentiment.
Overall, while the business fundamentals and dividend profile are sound, the current market price reflects a premium that may be difficult to sustain without clearer guidance or a shift in market sentiment.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below short‑term moving averages
- Bearish MACD and RSI indicating weak momentum
- Support level near $203.40 limiting downside
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- 10% revenue growth and solid margin profile
- Sustainable dividend yield of 2.41%
- Citi upgrade and positive earnings surprise
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Consistent cash flow generation and free cash flow
- Strategic initiatives in contractor services and e‑commerce
- Long‑term demographic tailwinds for home improvement spending
Key Metrics & Analysis
Financial Health
Revenue Growth10.30%
Profit Margin7.51%
P/E Ratio17.6
ROA12.79%
P/B Ratio-12.6
Op. Cash Flow$9.8B
Free Cash Flow$4.8B
Technical Analysis
TrendBearish
RSI32.9
Support$203.40
Resistance$235.60
MA 20$218.98
MA 50$231.33
MA 200$247.79
MACDBearish
VolumeIncreasing
Fear & Greed Index92.75
Valuation
Fair Value$100.82
Target Price$263.73
Upside/Downside27.01%
GradeOvervalued
TypeGrowth
Dividend Yield2.41%
Risk Assessment
Beta0.80
Volatility27.40%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.